Home / Health / Cancer Blood Test Edges Closer to FDA Approval
Cancer Blood Test Edges Closer to FDA Approval
2 Oct
Summary
- FDA panel backs Grail's Galleri test, citing benefits over risks.
- Approval could unlock significant US insurance coverage for tests.
- Multi-cancer tests aim to fill gaps where only five screenings exist.
An FDA advisory panel has recommended Grail's Galleri blood test, a significant advancement for early cancer detection. The panel concluded the test's potential benefits exceed its risks, paving the way for potential FDA approval in the coming months. This decision is crucial for Grail and similar tests, as it could unlock essential US health insurance coverage.
Currently, no multi-cancer blood test is FDA-approved, limiting coverage by Medicare and private insurers, leaving patients to pay out-of-pocket. However, FDA approval could make these tests eligible for Medicare coverage starting in 2028. Widespread insurance adoption could potentially create a substantial market, estimated to reach $60 billion annually in the US by 2030.
The Galleri test aims to detect signals for over 50 cancer types, addressing a critical gap in current screening, where only five cancers have established guidelines. While a UK trial showed mixed results initially, later findings indicated a reduction in late-stage diagnoses. Despite potential benefits, concerns remain regarding the anxiety and costs associated with positive results and the need for further diagnostic testing.
